Background:
Chronic pancreatitis is a progressive condition that impairs pancreatic function and is particularly challenging to manage in elderly patients.

Material and methods:
The study included 59 elderly patients with chronic pancreatitis who were monitored by their primary care physician. Participants were divided into two groups: Group 1 (n=29), who received treatment according to a standard chronic pancreatitis management protocol, and Group 2 (n=30), who received the same standard treatment plus intracellular systemic enzyme therapy.

Results:
Fecal α-elastase increased by 12.18% in Group 1 and 19.97% in Group 2, with Group 1 5.73% lower post-treatment (p<0.05). The Gastrointestinal Symptom Rating Scale (GSRS) scores showed greater reductions in Group 2, including abdominal pain (-39.04% vs. -30.53%) and indigestion (-31.83% vs. -26.39%) (p<0.05). Nutritional indicators improved more in Group 2, with higher total protein (+6.27% vs. +2.51%) and retinol levels (+57.58% vs. +28.13%) (p<0.05).

Conclusions:
The study found that intracellular systemic enzyme therapy significantly improved outcomes in elderly patients with chronic pancreatitis, including improved fecal α-elastase levels and better coprogram and ultrasound scores. Additionally, the therapy led to notable improvements in gastrointestinal symptoms and biochemical markers, suggesting its potential as a beneficial addition to chronic pancreatitis management.